“The present problem has uncovered some structural weaknesses while in the EU’s medicines provide chain plus a significant dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides claimed. She encouraged that supply chain issues be tackled in an EU pharmaceutic